CCDC expertise will contribute to CMAC’s quest to deliver new, more effective drugs to patients
The Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member in order to equip scientists in the field of pharmaceutical manufacturing with the tools required to master their structural data.
The CCDC maintains and curates the world’s most comprehensive and up-to-date database of small molecule crystal structures. With close to one million crystal structures, the database can be interrogated to address a range of questions in pharmaceutical development and manufacturing. These include assessing the risk of polymorphism of a drug candidate to designing a cocrystal solid form.
CCDC will create a bespoke crystal structure database for CMAC enabling scientists to inform and design continuous manufacturing processes. By automatically linking this novel database with other CMAC data scientists will have an incredible digital design tool to help tackle the challenges of advanced manufacturing.
Dr Ian Bruno, Director of Strategic Partnerships at the CCDC said: “We are delighted to strengthen our relationship with CMAC through this new partnership. This means that the researchers from the Hub will be able to get the most out of every crystal structure that they generate. It’s going to be fantastic to see what new and exciting insights they are going to gain from this collection of data!”
Dr Jürgen Harter, CCDC’s CEO, added: “It is excellent to see this partnership building - digital transformation of these processes needs to be underpinned by top quality scientific data, and the CCDC considers it a privilege to be part of this world class hub for pharmaceutical manufacture.”
CMAC Hub Director, Professor Alastair Florence, said: “The Hub has attracted many world-class organisations to join us in our quest to rapidly advance new drugs to market. As the leader in its field, I’m delighted that the CCDC is contributing its valuable expertise towards digital transformation of the production process”
The CMAC Future Manufacturing Research Hub is one of six hubs established around the UK in 2017 with funding from the UK government through the Engineering and Physical Sciences Research Council (EPSRC). It was developed in response to the need for innovative manufacturing processes to develop today’s medicines. They are also developing new flexible, integrated processing technologies to enable the supply chains of the future for new medicines.
In addition to the research team at Strathclyde, the Hub brings together leading academic groups at the Universities of Bath, Cambridge, Leeds, Loughborough, Sheffield and Imperial College London. CMAC’s vision has been developed through close collaboration with industry and the support of its Tier 1 partners, GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Takeda, Lilly, Roche and Pfizer and a wide range of Tier 2 technology companies.
The Cambridge Crystallographic Data Centre (CCDC) is the home of small molecule crystallography data and is a leader in software for pharmaceutical discovery, materials development, research and education.
The CCDC compiles and distributes the Cambridge Structural Database (CSD), the world's repository of experimentally determined organic and metal-organic crystal structures. We also produce associated knowledge-based application software for the global community of structural chemists.
Originating in the Department of Chemistry at the University of Cambridge, the CCDC is now a fully independent institution constituted as a non-profit company and a registered charity. With over 50 years of scientific expertise the CCDC has a strong track record in basic research through more than 750 peer-reviewed publications.
The CCDC employs around 70 staff in Cambridge, UK and Princeton, New Jersey, USA.
For more information contact:
Sales and Marketing Executive